Vanacker Hélène, Vinceneux Armelle, Nicolas-Virelizier Emmanuelle, Brahmi Mehdi, Cassier Philippe A
Centre Léon-Bérard, unité de phase précoces, oncologie médicale, 28, rue Laennec, 69008 Lyon, France; Université Claude Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69100 Villeurbanne, France.
Centre Léon-Bérard, unité de phase précoces, oncologie médicale, 28, rue Laennec, 69008 Lyon, France.
Bull Cancer. 2021 Oct;108(10S):S181-S194. doi: 10.1016/j.bulcan.2021.06.003.
Bispecific therapies targeting CD3, so-called T-cell engagers (TCE), belong to the new spectrum of anti-tumor immunotherapies stimulating T-lymphocytes. TCE are unique constructs targeting the MHC-independent CD3 epsilon subunit (CD3e) and a tumor antigen. To date, only blinatumomab have reached market agreements in lymphoid malignancies with constructs targeting CD3exCD19. Other TCE are in advances development, with promising results targeting CD20 and BSMA in lymphoma and myeloma. These successes have relaunched the development of TCE in solid tumors, bringing mixed results so far (notably in terms of tolerance). Still, TCE pave the way to new immunotherapy in tumors considered to be refractory to inhibitors of immune checkpoints such as prostate cancer or colorectal cancer.
靶向CD3的双特异性疗法，即所谓的T细胞衔接器（TCE），属于刺激T淋巴细胞的新型抗肿瘤免疫疗法。TCE是靶向不依赖主要组织相容性复合体（MHC）的CD3ε亚基（CD3e）和肿瘤抗原的独特构建体。迄今为止，只有博纳吐单抗在淋巴系统恶性肿瘤中就靶向CD3exCD19的构建体达成了上市协议。其他TCE正处于开发进展阶段，在淋巴瘤和骨髓瘤中靶向CD20和基底膜抗原（BSMA）取得了有前景的结果。这些成功重新推动了TCE在实体瘤中的开发，目前已取得了喜忧参半的结果（尤其是在耐受性方面）。尽管如此，TCE为在诸如前列腺癌或结直肠癌等被认为对免疫检查点抑制剂难治的肿瘤中开展新的免疫疗法铺平了道路。
